18 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 33000474 | Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report. | 2021 Mar | 1 |
2 | 33945921 | Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion. | 2021 | 1 |
3 | 34319660 | A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib. | 2021 Sep | 1 |
4 | 34511132 | Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. | 2021 Sep 13 | 1 |
5 | 34638496 | Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL). | 2021 Oct 7 | 1 |
6 | 32168429 | Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. | 2020 May | 2 |
7 | 32208297 | A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. | 2020 May | 1 |
8 | 33204104 | A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma. | 2020 | 3 |
9 | 31027745 | Next-Generation Sequencer Analysis of Pulmonary Pleomorphic Carcinoma With a CD74-ROS1 Fusion Successfully Treated With Crizotinib. | 2019 May | 1 |
10 | 29343973 | A patient with classic biphasic pulmonary blastoma harboring CD74-ROS1 fusion responds to crizotinib. | 2018 | 2 |
11 | 29477381 | CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib. | 2018 May 28 | 3 |
12 | 29704675 | Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. | 2018 Jul | 1 |
13 | 26673800 | A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. | 2016 May 15 | 3 |
14 | 25688157 | Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. | 2015 May 15 | 1 |
15 | 23724914 | Acquired resistance to crizotinib from a mutation in CD74-ROS1. | 2013 Jun 20 | 2 |
16 | 24047072 | Acquired resistance to crizotinib from a mutation in CD74-ROS1. | 2013 Sep 19 | 1 |
17 | 24047073 | Acquired resistance to crizotinib from a mutation in CD74-ROS1. | 2013 Sep 19 | 1 |
18 | 22215748 | ROS1 rearrangements define a unique molecular class of lung cancers. | 2012 Mar 10 | 1 |